Santarus Inc

Santarus — Investor Presentation (January 2006)

28 slides from Santarus's investor presentation, Jan 6, 2006

  1. Slide 1: Santarus (NasdaqNM: SNTS)

    NasdaqNM: SNTS

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation may include forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its

  3. Slide 3: Santarus Highlights

    Santarus Highlights Focused on U.S. Upper GI Rx market of $12+ billion Novel immediate-release omeprazole proton pump inhibitor (PPI) products Zegerid(r) Powder for Oral Suspension 20 mg & 40 mg (launched) NDAs under review with Q1 PDUFA dates Zegerid(r) Capsules (20 mg & 40 mg) - February 26, 2006

  4. Slide 4: Santarus Highlights

    Santarus Highlights Concentrated commercial target of 26,000 gastroenterologists and primary care physicians who prescribe ~ $4.6B of PPIs Greater than 250-member Santarus commercial team Attractive co-promotion agreement with Otsuka America Pharmaceutical (~170 sales reps) Strong intellectual prope

  5. Slide 5: Upper GI Products/Mechanisms

    Upper GI Products/Mechanisms STOMACH PROTON PUMPS ACID (HCL) ACETYLCHOLINE HISTAMINE ANTACIDS Neutralize existing acid Work quickly but produce only short term relief PROTON PUMP INHIBITORS Irreversibly bind to acid producing proton pumps and inhibit acid production regardless of pathway H2-RECEPTOR

  6. Slide 6: US PPI Prescription Market

    US PPI Prescription Market AstraZeneca Prilosec(r) $0.3B TAP Prevacid(r) $3.9B J&J Aciphex(r) $1.3B Wyeth Protonix(r) $2.5B AstraZeneca Nexium(r) $4.3B Generic Omeprazole $0.6B $12.9 Billion LTM November 2005 (Delayed-Release Products) Source: IMS Health, National Sales Perspective Audit

  7. Slide 7: US Prescription Mix for Leading Delayed-Release PPIs

    US Prescription Mix for Leading Delayed-Release PPIs 20 mg 40 mg 15 mg 30 mg 20 mg 40 mg 0.05 0.95 0 0.09 0.91 0 0.01 0.99 Source: IMS Health Nexium(r) Prevacid(r) Protonix(r) LTM November 2005

  8. Slide 8: Unmet Clinical Needs

    Unmet Clinical Needs Breakthrough heartburn - 50% of GERD patients Nocturnal heartburn - 79% of GERD patients Special populations - pediatrics, hospital, elderly Unmet Clinical Needs Create Market Opportunities Other Market Opportunities 1/3 of GERD visits are first-time visits PPI switching rate ~1

  9. Slide 9: Zegerid Product Family

    Zegerid(r) Product Family Dose Zegerid Powder For Oral Suspension 20 mg Heartburn/GERD, Erosive Esophagitis, Duodenal Ulcer Launched Oct 2004 Zegerid Capsules 40 mg Upper GI Bleeding in Critically Ill Patients, Gastric Ulcer Launched late Feb 2005 20 mg/ 40 mg Heartburn/GERD, Erosive Esophagitis, Du

  10. Slide 10: Effect of Zegerid Antacid on pH

    Effect of Zegerid(r) Antacid on pH Antacid buffer raises pH to >7 within 1 minute pH kinetic (acid infusion) in vitro model: Effect of 20 mEq sodium bicarbonate pH 3.5 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0 - -2 0 6 Time (minutes) Maintains pH to ^ 6.5 for about 30 minutes 14 22 30 38 pH 5.0 pH 6.0 pH 6.

  11. Slide 11: Zegerid Powder for Oral Suspension: Mean Plasma Omeprazole Concentrations

    Zegerid(r) Powder for Oral Suspension 20 mg: n=35 40 mg: n=32 Mean Plasma Omeprazole Concentrations Following a Morning Dose of Zegerid Powder for Oral Suspension and Prilosec(r) on Day 1 Peak blood levels reached in 30 minutes vs. 11/2 - 2 hours

  12. Slide 12: Zegerid Suspension Duration of Effect

    Zegerid(r) Suspension Duration of Effect Product Zegerid(r) Suspension Nexium(r) Prevacid(r) Aciphex(r) Protonix(r) Time Gastric pH > 4 30 mg/40 mg 18.6 hrs (40 mg) 16.8 hrs (40 mg) 15.8 hrs (30 mg) N/A N/A Time Gastric pH > 4 15 mg/20 mg 12.2 hrs (20 mg) 12.7 hrs (20 mg) 11.7 hrs (15 mg) 14.4 hrs (

  13. Slide 13: Zegerid Suspension Nighttime Acid Control

    Zegerid(r) Suspension Nighttime Acid Control Twice-Daily Dosing The pH data points correspond to the end of each 15-minute recording interval. Both trial drugs were administered at approximately 07:00 and 22:00hrs. Data obtained from open-label randomized crossover clinical study. Castell et al. Com

  14. Slide 14: Zegerid Once-Daily Evening Dosing vs. Protonix Twice-Daily

    Zegerid(r) Suspension Once-Daily Evening Dosing vs. Protonix(r) Twice-Daily Dosing Nighttime Median Gastric pH for 8 Hours Nighttime Median Gastric pH Zegerid 4.7 Protonix 1.7 Adapted from Castell et al. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantopr

  15. Slide 15: Zegerid Suspension Phase III Trial Results

    Zegerid(r) Suspension - Phase III Trial Results * 2-sided Fisher's Exact test ** 1-sided non-inferiority analysis pH Control and Upper GI Bleeding in Critically Ill Patients 105 58 32 34 7 10 0 20 40 60 80 100 120 140 IV Cimetidine (n=181) Zegerid Oral Suspension 40 mg (n=178) Number of Patients pH

  16. Slide 16: The Zegerid Difference

    The Zegerid(r) Difference Peak plasma levels in ~30 minutes 24-hour acid control Median gastric pH>4 for 18.6 hours with 40 mg dose Rapid and sustained gastric pH>4 with the first dose in critically ill patients QD (once a day) dosing any time of day Bedtime dosing provides nighttime acid control Sh

  17. Slide 17: Santarus Commercial Team

    Santarus Commercial Team Greater than 250-member commercial organization has significant depth of GI and pharmaceutical experience Average experience > 20 years Average experience > 10 years Average 5 years of experience - most w/ PPI selling experience National and regional account managers seek fo

  18. Slide 18: Managed Care Progress

    Managed Care Progress Claims approval rate* Zegerid(r) = ~90% Competitive products = ~94% Average co-pay* Zegerid = ~$36.00 Competitive products = $27.00 to $30.00 Zegerid is on Tier 3 on most plans Efforts directed at reducing/removing prior authorizations and moving Zegerid to Tier 2 as contracts

  19. Slide 19: Launch Weekly Prescribers of Zegerid

    40 mg Launch Weekly Prescribers of Zegerid(r) Source: NDCHealth

  20. Slide 20: Zegerid Monthly Prescriptions

    Zegerid(r) Monthly Prescriptions Source: IMS NPA - TRx (Retail & Mail Order)

  21. Slide 21: Zegerid NRx and TRx 2005 Monthly Data

    Zegerid(r) NRx and TRx 2005 Monthly Data NRx TRx Jan 2566 3406 Feb 2713 3748 Mar 4468 5846 Apr 5164 6954 May 5767 8270 Jun 6156 9322 Jul 6219 9866 Aug 7853 12171 Sep 7812 12481 Oct 8155 13441 Nov 8966 14759 Scripts *40 mg launched late February Source: IMS NPA (Retail & Mail Order)

  22. Slide 22: Zegerid vs Prevacid Suspension Total Prescriptions

    Zegerid(r) vs Prevacid(r) Suspension Total Prescriptions Zegerid has gained a significant share of the U.S. PPI suspension market Source: IMS Health

  23. Slide 23: Commercialization of Zegerid Brand

    Commercialization of Zegerid(r) Brand 2006 & Beyond 2005 2004 Strategic Collaborations Zegerid(r) Powder for Oral Suspension 40 mg Zegerid(r) Powder for Oral Suspension 20 mg Zegerid(r) Chewable Tablets Zegerid(r) Capsules OTC Ex-U.S. Pediatric Mkt. Broaden Reach Otsuka America - U.S. Co-promotion

  24. Slide 24: Co-promotion Partner Otsuka America Pharmaceutical

    Co-promotion Partner Otsuka America Pharmaceutical Non-exclusive agreement to co-promote in US Zegerid(r) Powder for Oral Suspension and Zegerid Capsules (assuming FDA approval) ~170 Otsuka sales representatives promoting Zegerid in first position sales call to our target physicians $15 million upfr

  25. Slide 25: Strong Intellectual Property Portfolio

    Strong Intellectual Property Portfolio Exclusive worldwide license agreement with the University of Missouri Five issued US patents expire in 2016 Patents cover all currently marketed PPIs with antacids and other buffering agents in various liquid & solid formulations Applications pending in US and

  26. Slide 26: 2005 Financial Highlights (unaudited)

    2005 Financial Highlights (unaudited) *Includes $10 million milestone payment from TAP Cash, cash equivalents & short-term investments: $86 million at September 30, 2005 Santarus plans to continue to invest in activities to build the Zegerid(r) brand 3/31/2005 6/30/2005 9/30/2005 9/30/2005 Revenue $

  27. Slide 27: Recent Key Accomplishments

    Recent Key Accomplishments Published data from upper GI bleeding clinical study in Critical Care Medicine Apr 2005 Submitted NDAs for Zegerid(r) solid dosage formulations Capsule Chewable Apr 2005 May 2005 Published clinical study results to differentiate Zegerid from Protonix(r) for control of noct

  28. Slide 28: Future Milestones

    Future Milestones Establish Zegerid(r) brand as the only Immediate-Release oral PPI in $12.5 billion U.S. PPI market Receive FDA decision on two NDAs in Q1 2006 Zegerid Capsules in late February 2006 Zegerid Chewable Tablets in late March 2006 Launch Zegerid Capsules in Q1 2006, assuming approval Bu

Santarus — Investor Presentation (January 2006) on 6ix